Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference

NEXT STORY
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
PREV STORY
AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases

author_avatar
NASDAQ Market News

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

author_avatar
NASDAQ Market News

Valneva: US DoD Exercises Option on IXIARO® Supply Contract Bringing Total Value to $70 Million

author_avatar
NASDAQ Market News